Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study

A. Veronesi; V. Dal Bo; G. Lo Re; M. Della Valentina; U. Tirelli; A. Merlo; R. Talamini; M. Francini; S. Monfardini

doi:10.1007/BF00273528

Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study

A. Veronesi, V. Dal Bo, G. Lo Re, M. Della Valentina, U. Tirelli, A. Merlo, R. Talamini, M. Francini, S. Monfardini

Research output: Contribution to journal › Article › peer-review

Abstract

From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m² every 6 weeks (15 mg/m² in patients >75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR+PR; however, a beneficial symptomatic effect was frequently observed.

Original language	English
Pages (from-to)	115-116
Number of pages	2
Journal	Cancer Chemotherapy and Pharmacology
Volume	23
Issue number	2
DOIs	https://doi.org/10.1007/BF00273528
Publication status	Published - Feb 1989

ASJC Scopus subject areas

Pharmacology
Oncology
Cancer Research

Access to Document

10.1007/BF00273528

Cite this

@article{f9fea568cfe94c1e86c5ceeb647e7fbe,

title = "Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study",

abstract = "From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m2 every 6 weeks (15 mg/m2 in patients >75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR+PR; however, a beneficial symptomatic effect was frequently observed.",

author = "A. Veronesi and Bo, {V. Dal} and Re, {G. Lo} and Valentina, {M. Della} and U. Tirelli and A. Merlo and R. Talamini and M. Francini and S. Monfardini",

year = "1989",

month = feb,

doi = "10.1007/BF00273528",

language = "English",

volume = "23",

pages = "115--116",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma

T2 - a phase II study

AU - Veronesi, A.

AU - Bo, V. Dal

AU - Re, G. Lo

AU - Valentina, M. Della

AU - Tirelli, U.

AU - Merlo, A.

AU - Talamini, R.

AU - Francini, M.

AU - Monfardini, S.

PY - 1989/2

Y1 - 1989/2

N2 - From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m2 every 6 weeks (15 mg/m2 in patients >75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR+PR; however, a beneficial symptomatic effect was frequently observed.

AB - From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m2 every 6 weeks (15 mg/m2 in patients >75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR+PR; however, a beneficial symptomatic effect was frequently observed.

UR - http://www.scopus.com/inward/record.url?scp=0024264919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024264919&partnerID=8YFLogxK

U2 - 10.1007/BF00273528

DO - 10.1007/BF00273528

M3 - Article

C2 - 2491963

AN - SCOPUS:0024264919

VL - 23

SP - 115

EP - 116

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -

Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this